Xeris Lifts 2026 Revenue Forecast to $395 Million-$405 Million
Photo: TokenPost
Xeris Biopharma Holdings raised its full-year 2026 revenue guidance to $395 million-$405 million with its third-quarter results on Nov. 5. The new range replaces the $385 million-$390 million forecast issued Aug. 6. Xeris also increased its 2030 revenue outlook from approximately $750 million to more than $1 billion. Revenue for the three months ended Sept. 30 was $107.225 million, compared with $74.380 million in the same period a year earlier. Recorlev revenue climbed 93% to $71.540 million. Gvoke revenue declined 14% to $21.706 million, while Keveyis revenue rose 9% to $13.021 million.
Source: TokenPost
